We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-2.15%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$574M
AUM Growth
-$338M
Cap. Flow
-$522M
Cap. Flow %
-91.01%
Top 10 Hldgs %
44.83%
Holding
163
New
26
Increased
13
Reduced
41
Closed
50

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$12.3M
2
AMGN icon
Amgen
AMGN
+$11.3M
3
SLN
Silence Therapeutics
SLN
+$10.8M
4
VKTX icon
Viking Therapeutics
VKTX
+$9.06M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$6.59M

Top Sells

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$10.5M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$10.4M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.14M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.96M
5
ANNX icon
Annexon
ANNX
+$5.3M

Sector Composition

Rank Sector Weight
1 Healthcare 55.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
CALL
Alnylam Pharmaceuticals
ALNY
$35.9B
$36.5M 6.35%
1,500
-119,300
-99% -$18.8M
ALNY icon
2
PUT
Alnylam Pharmaceuticals
ALNY
$35.9B
$36.5M 6.35%
1,500
-135,200
-99% -$21.3M
INSM icon
3
CALL
Insmed
INSM
$23.3B
$34M 5.92%
5,070
-342,130
-99% -$13.3M
SRPT icon
4
Sarepta Therapeutics
SRPT
$1.68B
$32.2M 5.6%
203,612
+51,334
+34% +$6.59M
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$8.85B
$26.4M 4.59%
588,818
-54,933
-9% -$2.54M
TARS icon
6
Tarsus Pharmaceuticals
TARS
$2.56B
$21.8M 3.79%
800,277
+90,000
+13% +$3.03M
AMGN icon
7
CALL
Amgen
AMGN
$201B
$18.7M 3.27%
600
-59,400
-99% -$17.5M
SLNO
8
DELISTED
Soleno Therapeutics
SLNO
$18.2M 3.17%
445,451
-119,960
-21% -$5.08M
PRAX icon
9
PUT
Praxis Precision Medicines
PRAX
$8.99B
$17.5M 3.04%
+4,225
New +$200K
SRPT icon
10
CALL
Sarepta Therapeutics
SRPT
$1.68B
$15.8M 2.75%
1,000
-115,100
-99% -$14.8M
BBIO icon
11
CALL
BridgeBio Pharma
BBIO
$16.2B
$15.2M 2.65%
6,000
-383,400
-98% -$10.5M
CRBP icon
12
Corbus Pharmaceuticals
CRBP
$173M
$14M 2.44%
309,540
-249,731
-45% -$10.5M
NBIX icon
13
CALL
Neurocrine Biosciences
NBIX
$17.5B
$13.8M 2.4%
+1,000
New +$137K
ELVN icon
14
Enliven Therapeutics
ELVN
$3.77B
$13.7M 2.39%
+586,552
New +$12.3M
PRAX icon
15
CALL
Praxis Precision Medicines
PRAX
$8.99B
$12.4M 2.16%
3,000
-18,800
-86% -$888K
AMGN icon
16
Amgen
AMGN
$201B
$12M 2.08%
+38,300
New +$11.3M
NUVL
17
DELISTED
Nuvalent
NUVL
$11.5M 2%
151,601
+50,000
+49% +$3.56M
CYTK icon
18
Cytokinetics
CYTK
$11.1B
$9.22M 1.61%
170,147
+25,000
+17% +$1.51M
NRIX icon
19
Nurix Therapeutics
NRIX
$2.46B
$9.19M 1.6%
440,500
+140,500
+47% +$2.19M
ARE icon
20
PUT
Alexandria Real Estate Equities
ARE
$8.73B
$8.57M 1.49%
733
-72,567
-99% -$8.65M
AZN icon
21
CALL
AstraZeneca
AZN
$261B
$8.52M 1.48%
546
-154,054
-100% -$23.2M
BBIO icon
22
BridgeBio Pharma
BBIO
$16.2B
$8.41M 1.47%
332,013
+50,000
+18% +$1.37M
CPRX
23
DELISTED
Catalyst Pharmaceutical
CPRX
$8.03M 1.4%
518,386
– –
VKTX icon
24
Viking Therapeutics
VKTX
$4.11B
$7.33M 1.28%
+138,262
New +$9.06M
IMVT icon
25
Immunovant
IMVT
$8.08B
$7.31M 1.27%
276,925
– –
1
2 3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Ikarian Capital held 163 positions worth $574M, down 37% from $912M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Ikarian Capital withdrew a net $522M in Q2 2024, closing 50 positions and reducing 41 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $10.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 40% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Enliven Therapeutics worth $13.7M.

  • Ikarian Capital's largest Q2 2024 buy was Enliven Therapeutics: 586,552 shares worth $13.7M.
  • Ikarian Capital added most to Sarepta Therapeutics in Q2 2024, an estimated $6.59M increase.
  • Ikarian Capital's biggest Q2 2024 reduction was Corbus Pharmaceuticals, cutting an estimated $10.5M.
  • Ikarian Capital fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $10.4M.
  • Ikarian Capital's ten largest holdings make up 45% of its $574M portfolio in Q2 2024.
  • Ikarian Capital opened 26 new positions and closed 50 in Q2 2024.
  • Ikarian Capital's portfolio value fell 37% quarter-over-quarter to $574M.

Based on Ikarian Capital's 13F filing for Q2 2024, filed 14 Aug 2024.